Real-world Evidence Solutions Market

Based on component, the services segment held the largest share of the RWE solutions market, driven by the growing demand for specialized expertise in RWE study design, data management, epidemiology, biostatistics, HEOR, regulatory support, and evidence generation. As RWE studies increasingly involve complex datasets and require alignment with regulatory and payer requirements, pharmaceutical and medtech companies often rely on specialized service providers to manage the end-to-end evidence-generation process. Companies such as ICON supported a pharmaceutical company with a rare molecular subtype of a solid tumor where conducting a conventional post-approval clinical trial was difficult because of the very small patient population. ICON proposed using a clinico-genomic real-world database to generate evidence instead of initiating a new trial.

Based on application, the drug development & approvals segment held the largest share of the RWE solutions market, supported by the increasing use of real-world data to complement clinical trial evidence. RWE helps pharmaceutical companies with patient identification, clinical trial design, external control arms, treatment effectiveness and safety assessment, label expansion, and regulatory submissions. Growing regulatory acceptance of RWE is further strengthening its role across the drug development lifecycle. For example, in April 2025, the FDA expanded Isturisa (osilodrostat) to treat adults with Cushing’s syndrome regardless of underlying cause. Real-world evidence from the LINC7 retrospective cohort study in France provided confirmatory evidence for the regulatory decision, showing how RWE can complement clinical-trial evidence to support label expansions.

Based on revenue model, the subscription segment held the largest share of the RWE solutions market, as pharmaceutical, biotechnology, and healthcare organizations increasingly require continuous access to RWD, analytics platforms, patient-level datasets, and evidence-generation tools. Subscription-based models provide recurring access to updated datasets and analytical capabilities, allowing users to conduct multiple RWE studies without purchasing individual datasets or projects. RWE data providers such as TriNetX use platform-based access models that enable life sciences organizations to continuously access de-identified healthcare data and analytics for patient population analysis, clinical trial planning, treatment-pattern studies, and outcomes research.

Based on deployment model, the cloud-based segment held the largest share of the RWE solutions market, driven by the growing need to store, integrate, and analyze large volumes of real-world data from EHRs, claims, registries, wearables, and other healthcare sources. Cloud platforms provide scalable infrastructure, centralized data access, and advanced analytics capabilities, enabling pharmaceutical and healthcare organizations to conduct RWE studies more efficiently and across larger patient populations. IQVIA provides cloud-enabled access to large-scale RWD through its Analytics Research Accelerator, allowing users to discover, access, integrate, and analyze healthcare datasets through cloud environments such as Snowflake and AWS S3.

Based on end user, the pharmaceutical and biotechnology companies segment held the largest share of the RWE solutions market, driven by their extensive use of real-world data across the drug lifecycle. RWE is increasingly used for clinical development, patient population identification, external control arms, safety and effectiveness assessment, regulatory submissions, label expansion, and post-market studies. The growing regulatory acceptance of RWE is further encouraging adoption among drug developers. FDA data show that RWE-containing protocols submitted to CDER increased from 10 in FY2023 to 31 in FY2025, highlighting the expanding role of RWE in drug development.